Previous 10 | Next 10 |
2023-04-13 15:59:42 ET Shares of gene editing companies rose Thursday as Wall Street took notice of the underperforming subsector issuing a series of bullish views despite the recent selloff. Notable gainers include Editas Medicine ( NASDAQ: EDIT ), Sangamo Therapeutics ( SG...
2023-04-13 11:58:37 ET Shares of CRISPR Therapeutics (NASDAQ: CRSP) were up 15% Thursday morning, a day after a drug-pricing group said the company's single-dose therapy for sickle cell disease (SCD) could be cost effective if priced below $1.9 million. CRISPR is developing exa-...
2023-04-13 10:50:19 ET The influential drug pricing watchdog, Institute for Clinical and Economic Review (ICER) says that upcoming sickle cell disease therapies, exa-cel, and lovo-cel, would be cost-effective if priced at up to $1.9M. "From the earliest days of gene therapy, patients, f...
2023-04-13 10:40:48 ET Swiss biotech CRISPR Therapeutics ( NASDAQ: CRSP ) added ~15% on Thursday after Cantor Fitzgerald launched its coverage with an Overweight rating and a $72 per share target expecting a potential FDA nod for its gene-editing therapy exa-cel. Early this ...
2023-04-13 10:15:00 ET Among the growth-heavy stocks of the Nasdaq Composite , a few companies stand out as being especially promising. At the moment, two enterprising biopharma players -- Vertex Pharmaceuticals (NASDAQ: VRTX) and CRISPR Therapeutics (NASDAQ: CRSP) ...
2023-04-12 05:30:00 ET Vertex Pharmaceuticals (NASDAQ: VRTX) recently reported great news. It completed the submission of exa-cel, its treatment candidate for blood disorders, to the U.S. Food and Drug Administration (FDA). The company and partner CRISPR Therapeutics (NASDAQ: ...
2023-04-10 10:48:10 ET A group of senior pharma executives, including Pfizer ( NYSE: PFE ) chief executive Albert Bourla, has come forward in support of the FDA after a Texas-based judge suspended the approval of abortion treatment mifepristone on Friday. Mifepristone, appro...
2023-04-08 05:30:00 ET CRISPR Therapeutics (NASDAQ: CRSP) works in the cutting-edge space of gene editing. The biotech company uses the CRISPR/Cas9 technique, which involves cutting DNA at a certain point and letting a natural repair process take place. It's a way to "fix" faulty ge...
2023-04-06 08:00:00 ET The last 12 months haven't been kind to the likes of gene editing stocks like CRISPR Therapeutics (NASDAQ: CRSP) and Bluebird Bio (NASDAQ: BLUE) . Whereas CRISPR's shares fell by 31%, Bluebird's are down by 33%. But now, both businesses have major cata...
2023-04-04 14:00:00 ET Vertex Pharmaceuticals (NASDAQ: VRTX) has been generating billion-dollar revenue for years, thanks to its portfolio of cystic fibrosis (CF) drugs. In fact, Vertex is the global leader in CF treatment and likely to hang onto that position for quite some time. B...
News, Short Squeeze, Breakout and More Instantly...
CRISPR Therapeutics AG Company Name:
CRSP Stock Symbol:
NASDAQ Market:
CRISPR Therapeutics AG Website: